Compare AstraZeneca plc (AZN) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? AstraZeneca plc trades at $157.95 (market cap $248.14B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: AstraZeneca plc pays a 2.01% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | SGOV | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Fixed Income |
52-Week High | $209.48 | $100.74 |
52-Week Low | $147.06 | $100.28 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.51 with minimal daily movement, reflecting its role as a stable cash alternative. The ETF maintains a bearish technical signal from moving averages while oscillators show neutral momentum. Recent institutional activity includes mixed positioning changes, with Bank of America increasing holdings while Deane Retirement Strategies significantly reduced exposure. The fund offers monthly distributions with a current yield around 3.8%, attracting defensive positioning amid market volatility.
SGOV provides principal protection and liquidity with minimal interest rate risk, making it suitable for conservative investors seeking yield above traditional savings. Key risks include Federal Reserve policy changes impacting short-term rates and inflation dynamics affecting real returns. The ETF's stability and monthly income stream offer defensive characteristics during economic uncertainty, though limited upside potential compared to equity investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
